Dopamine receptor subtypes: Differential regulation after 8 months treatment with antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 561-569

  Florijn, Wouter J ^a,b   Tarazi, Frank I ^a,c   Creese, Ian ^a  

^a RUTGERS UNIVERSITY   (United States)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; EMONAPRIDE; HALOPERIDOL; RACLOPRIDE; RECEPTOR SUBTYPE; SPIPERONE; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; LIGAND BINDING; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SCHIZOPHRENIA; STRIATE CORTEX;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; CLOZAPINE; CORPUS STRIATUM; HALOPERIDOL; IODINE RADIOISOTOPES; MALE; ORGAN SPECIFICITY; RACLOPRIDE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SALICYLAMIDES; SPIPERONE; TETRAHYDRONAPHTHALENES; TIME FACTORS; TRITIUM; UP-REGULATION;

EID: 0030980673     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. 1 antagonists. Naunyn-Schmiedeberg Arch. Pharmacol 338: 162-168, 1988.
2. 2) receptor binding in the frontal cortex of schizophrenic patients. J. Neurotransm. 85: 19-29, 1991.
3. BALDESSARINI, R. J. AND TARAZI, F. I.: Brain dopamine receptors: A primer on their current status, basic and clinical. Harvard Rev Psychiatry 3: 301-325, 1996.
4. BALDESSARINI, R. J. AND TARSY, D.: Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Ann. Rev. Neurosci. 3: 23-41, 1980.
5. BERGER, B., GASPAR, P. AND VERNEY, C.: Dopaminergic innervation of the cerebral cortex: Unexpected differences between rodents and primates. Trends Neurosci. 14: 21-27, 1991.
6. BURT, D. R., CREESE, I. AND SNYDER, S. H.: Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 196: 326-328, 1977.
7. CASEY, D. E.: Extrapyramidal syndromes in non-human primates: typical and atypical neuroleptics, Psychopharm. Bull. 27: 47-50, 1991.
8. CHIODO, L. A. AND BUNNEY, B. S.: Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3: 1687-1693, 1983.
9. CLOW, A., THEODOROU, A., JENNER, P. AND MARSDEN, C. D.: Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur. J. Pharmacol. 63: 145-157, 1980.
10. 1 receptors. J. Pharmacol. Exp. Ther. 249: 769-776, 1989.
11. 2 receptor blocker, in acute schizophrenia: An open trial. Int. Clin. Psychopharmacol. 4: 61-70, 1989.
12. CREESE, I., BURT, D. R. AND SNYDER, S. H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483, 1976.
13. 2 dopamine mRNAs: Ontogenetic and pharmacological studies. Neurochem. Int. 20: 45S-48S, 1992.
14. 2 dopamine receptors: Mutation of a histidine residue specifically affects the binding of a subgroup of substituted benzamide drugs. J. Neurochem. 62: 1664-1669, 1994.
15. 1dopamine receptors in the rat brain: A quantitative autoradiograpic analysis. J. Neurosci. 6: 2352-2365, 1986.
16. 1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121: 323-327, 1995.
17. 2 receptors. Biochemistry 34: 13635-13641, 1995.
18. 2 receptors in the effects of classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur. J. Pharmacol. 196: 103-108, 1991.
19. ELLISON, G., SEE, R., LEVIN, E. AND KINNEY, J.: Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology 92: 122-126, 1987.
20. FARDE, L., WIESEL, F-A., JANSSEN, P., UPPFELDT, G., WAHLEN, A. AND SEDVALL, G.: An open label trial of raclopride in acute schizophrenia: confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 94: 1-7, 1988.
21. 11C]racloPride. Arch Gen Psychiatry 47: 213-219, 1990.
22. 4 receptor binding using antisense oligonucleotides (Abstract 377.7). Soc. Neurosci. Abstr. 20: 909, 1994.
23. 1 receptor antagonist NNC-756. Eur. J. Pharmacol. 242: 283-291, 1993.
24. GUNNE, L. M., ANDERSSEN, U., BONDESSON, U. AND JOHANSSON, P.: Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav. 25: 897-901, 1986.
25. 1 receptor antagonism in schizophrenia: is there a reduced risk of extrapyramidal side-effects? Trends Pharmacol. Sci. 11: 406-410, 1990.
26. 2 receptors: Distribution, pharmacological characterization and region-specific regulation by clozapine. J. Pharmacol. Exp. Ther. 261: 1282-1290, 1992.
27. JESTE. D. V. AND WYATT, R. J.: In search of a treatment for tardive dyskinesia: Review of the literature. Schizophrenia Bull. 5: 251-292, 1979.
28. JOYCE, J.: The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology 112: S16-S34, 1993.
29. KAKIGI, T., GAO, X.-M. AND TAMMINGA, C. A.: Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J. Neural. Transm. 101: 41-49, 1995.
30. 1 dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121: 309-316, 1995.
31. 3H-raclopride. Neurosci. Lett. 66: 85-90, 1986.
32. 3H-hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U.S.A. 89: 8155-8159, 1992.
33. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 92: 1719-1723, 1995.
34. 2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 91: 4353-4356, 1994.
35. 125I-iodosulpiride. Eur. J. Pharmacol. 118: 211-219, 1985.
36. 4 receptor in human cerebral cortex and striatum. J. Neurochem. 66: 915-919, 1996.
37. 2 receptor mRNA level in rat striatum after chronic haloperidol treatment. Neurosci. Res. 12: 440-445, 1991.
38. 4 receptors in GABAergic neurons of the primate brain. Nature 381: 245-248, 1996.
39. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15: 2186-219, 1995.
40. MURUGAIAH, K., FLEMINGER, S., THEODOROU, A., JENNER, P. AND MARSDEN, C. A.: Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake. Biochem. Pharmacol. 32: 2495-2499, 1983.
41. O'DELL, S. J., LA HOSTE, G. J., WIDMARK, C. B., SHAPIRO, R. M., POTKIN, S. G. AND MARSHALL, J. F.: Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146-153, 1990.
42. 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration. Life Sci. 26: 55-60, 1980.
43. 3H-Spiperone binding sites in brain: autoradiographic localization of multiple receptors. Brain Res. 213: 277-289, 1981.
44. 2 dopamine receptor reappearance after irreversible receptor blockade. Brain Res. 435: 147-152, 1988.
45. 1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur. J. Pharmacol. 202: 273-276, 1991.
46. RUPNIAK, N. M. J., MANN, S., HALL, M. D., FLEMINGER, S., KILPATRICK, G., JENNER, P. AND MARSDEN, C. D.: Differential effects of continous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology 4: 503-511, 1984.
47. 4 receptors by 2-fold in rats. Eur. J. Pharmacol. 289: 67-72, 1995.
48. 3 receptors in vivo. Eur. J. Pharmacol. 218: 373-375, 1992.
49. SEEMAN, P.: Brain dopamine receptors. Pharmacol. Rev. 32: 229-313, 1980.
50. 4. Neuropsychopharmacology 7: 261-285, 1992.
51. 4 receptors elevated in schizophrenia. Nature 365: 441-445, 1993.
52. SEEMAN, P., LEE, T., CHAU-WONG, M. AND WONG, K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719, 1976.
53. 3H-nemonapride. J. Neurochem. 64: 1413-1415, 1995.
54. SHIRAKAWA, O. AND TAMMINGA, C. A.: Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesia in rat. Exp. Neurol. 127: 62-69, 1994.
55. SIBLEY, D. R. AND MONSMA, F. J.: Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13: 61-69, 1992.
56. 3 as a target for neuroleptics. Nature 347: 146-151, 1990.
57. SOKOLOFF, P. AND SCHWARTZ, J-C.: Novel dopamine receptors half a decade later. Trends Pharmacol. Sci. 16: 270-275, 1995.
58. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681: 109-116, 1995.
59. 1. Nature 350: 610-614, 1991.
60. TARAZI, F. I., FLORIJN, W. J. AND CREESE, I.: Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience 1997, in press.
61. TARAZI, F. I., SHIRAKAWA, O. AND TAMMINGA, C. A.: Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects. Eur. J. Pharmacol. 232: 71-77, 1993.
62. 2 receptor binding to rat striatum. Eur. J. Pharmacol. 173: 177-182, 1989.
63. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350: 614-619, 1991.
64. 2 dopamine receptor mRNA levels. Neurosci. Lett. 111: 303-308, 1990.
65. 1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes. Eur. J. Pharmacol. 269: 121-125, 1994.
66. WHITE, F. J. AND WANG, R. X.: Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054-1057, 1983.
67. 2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558-1563, 1986.
68. 2 receptor group, in the rat brain and spinal cord. J. Comp. Neurol. 344: 121-136, 1994.
69. 3H-spiperone in striatum. J. Pharmacol. Exp. Ther. 227: 593-599, 1983.
70. 1 dopamine receptors. Nature 347: 77-80, 1990.